Molecular mechanisms of new immunosuppressants - PubMed (original) (raw)
Review
. 1996 Feb;10(1 Pt 2):118-23.
Affiliations
- PMID: 8680047
Review
Molecular mechanisms of new immunosuppressants
P F Halloran. Clin Transplant. 1996 Feb.
Abstract
Maintenance immunosuppressive drugs act by partially blocking rate-limiting steps in the immune response. The new maintenance immunosuppressive drugs are either inhibitors of de novo synthesis of nucleotides (purines or pyrimidines), or are immunophilin-binding drugs that inhibit signal transduction in lymphocytes. The new inhibitors of de novo nucleotide synthesis include mycophenolate mofetil (MMF), mizoribine (MZ), brequinar (BQR), and leflunomide (LEF). MMF and MZ act to inhibit de novo purine synthesis, by inhibition of inosine monophosphate dehydrogenase (IMPDH). They create a selective immunodeficiency in T and B lymphocytes. MMF is hydrolyzed to mycophenolic acid (MPA), an uncompetitive inhibitor of IMPDH. MPA reduces the pools of guanine nucleotides, and increases some adenine nucleotides, inhibiting the cell cycle. Thus the number of specific effector T and B lymphocytes is reduced by limiting clonal expansion. MZ is a competitive inhibitor of IMPDH, which creates a similar defect. The relative clinical effectiveness of MMF versus MZ is not known. MMF has been approved in a number of countries; MZ has been approved in Japan. The inhibitors of de novo pyrimidine synthesis (BQR, LEF) act on the enzyme dehydroorotate dehydrogenase. Neither is currently in clinical trials in transplantation. The new immunophilin-binding drugs inhibit either the calcium-dependent phosphatase calcineurin (CN) [tacrolimus (or FK-506) and the microemulsion form of cyclosporine (CsA)] or signaling from growth factor receptors [rapamycin (sirolimus)]. Tacrolimus binds to FK binding protein-12 (FKBP-12) to create a complex that inhibits CN. CsA binds to cyclophilin to create a complex that inhibits CN. Inhibition of CN prevents activation of cytokine genes in T cells. The relative clinic effectiveness of tacrolimus versus microemulsion CsA is unknown. Rapamycin inhibits signaling from growth factor receptors, such as IL-2R. Rapamycin binds to FKBP to create a complex that engages proteins called TOR (target of rapamycin), or RAFT (rapamycin and FKBP target), which may be kinases. The result is a block in the ability of cytokine receptors to activate cell cycling, interfering with clonal expression. Deoxyspergualin, a parenteral drug in development for induction or antirejection therapy, may inhibit intracellular chaperoning by Hsc70, a member of the heat shock protein family. It may have its principal effect by inhibiting the activation of transcription factor NF-kappa B in antigen-presenting cells and monocytes.
Similar articles
- New small molecule immunosuppressants for transplantation: review of essential concepts.
Morris RE. Morris RE. J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 2):S275-86. J Heart Lung Transplant. 1993. PMID: 7508752 Review. - The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.
Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M, et al. Dumont FJ, et al. J Exp Med. 1992 Sep 1;176(3):751-60. doi: 10.1084/jem.176.3.751. J Exp Med. 1992. PMID: 1380976 Free PMC article. - Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin.
Bell A, Wernli B, Franklin RM. Bell A, et al. Biochem Pharmacol. 1994 Aug 3;48(3):495-503. doi: 10.1016/0006-2952(94)90279-8. Biochem Pharmacol. 1994. PMID: 7520696 - Cyclosporin A, FK506 and rapamycin: more than just immunosuppression.
Kunz J, Hall MN. Kunz J, et al. Trends Biochem Sci. 1993 Sep;18(9):334-8. doi: 10.1016/0968-0004(93)90069-y. Trends Biochem Sci. 1993. PMID: 7694398 Review. - Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.
Sigal NH, Dumont FJ. Sigal NH, et al. Annu Rev Immunol. 1992;10:519-60. doi: 10.1146/annurev.iy.10.040192.002511. Annu Rev Immunol. 1992. PMID: 1375473 Review.
Cited by
- ASS1igning purine dependency to cancer.
Villa E, Ben-Sahra I. Villa E, et al. Nat Cancer. 2020 Sep;1(9):862-863. doi: 10.1038/s43018-020-00117-0. Nat Cancer. 2020. PMID: 35121954 No abstract available. - Recent Advances in Liposomal-Based Anti-Inflammatory Therapy.
van Alem CMA, Metselaar JM, van Kooten C, Rotmans JI. van Alem CMA, et al. Pharmaceutics. 2021 Jul 1;13(7):1004. doi: 10.3390/pharmaceutics13071004. Pharmaceutics. 2021. PMID: 34371695 Free PMC article. Review. - Bioprocess and genetic engineering aspects of ascomycin production: a review.
Sambyal K, Singh RV. Sambyal K, et al. J Genet Eng Biotechnol. 2020 Nov 19;18(1):73. doi: 10.1186/s43141-020-00092-0. J Genet Eng Biotechnol. 2020. PMID: 33215240 Free PMC article. Review. - Ehrlichia canis in dogs experimentally infected, treated, and then immune suppressed during the acute or subclinical phases.
Sato M, Veir JK, Shropshire SB, Lappin MR. Sato M, et al. J Vet Intern Med. 2020 May;34(3):1214-1221. doi: 10.1111/jvim.15750. Epub 2020 Apr 8. J Vet Intern Med. 2020. PMID: 32267035 Free PMC article. - Development and characterization of methoxy poly(ethylene oxide)-_block_-poly(ε-caprolactone) (PEO-_b_-PCL) micelles as vehicles for the solubilization and delivery of tacrolimus.
Ali R, Farah A, Binkhathlan Z. Ali R, et al. Saudi Pharm J. 2017 Feb;25(2):258-265. doi: 10.1016/j.jsps.2016.06.009. Epub 2016 Jul 1. Saudi Pharm J. 2017. PMID: 28344477 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous